Research Topics
Genomes and Genes | Hiroshi MiyamotoSummaryAffiliation: University of Rochester Country: USA Publications
| Collaborators
|
Detail Information
Publications
Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinomaH Miyamoto
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
Curr Cancer Drug Targets 12:14-22. 2012..Considerable uncertainty remains regarding the selection of patients who are likely to benefit from hormonal therapy and optimal options for the treatment...- Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification systemHiroshi Miyamoto
Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Pathol Int 60:1-8. 2010..This article outlines the 2004 WHO/ISUP classification system regarding the specific histological criteria for non-invasive papillary urothelial neoplasms and the clinical significance of each category... - Identification of steroid derivatives that function as potent antiandrogensHiroshi Miyamoto
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
Int J Cancer 117:866-72. 2005..These results strengthen our hypothesis and suggest that selective steroid derivatives could be potent antiandrogenic drugs with less unfavorable effects for the treatment of prostate cancer... - Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cellsMujib M Rahman
George Whipple Laboratory for Cancer Research, Department of Biochemistry, and the Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
Proc Natl Acad Sci U S A 100:5124-9. 2003.... - Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54Zhiming Yang
George Whipple Lab for Cancer Research, and University of Rochester Medical Center, Rochester, NY 14642, USA
Endocrinology 148:1340-9. 2007..The novel finding that a protein can modulate AR function without direct interaction with AR might provide a new therapeutic approach to battle prostate cancer by targeting AR indirectly with fewer side effects... - 3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activityHiroshi Miyamoto
George Whipple Laboratory for Cancer Research, Department of Pathology, and the Cancer Center, University of Rochester, Rochester, NY 14642, USA
Proc Natl Acad Sci U S A 100:4440-4. 2003..Further in vivo studies might facilitate the development of a better antiandrogen for the treatment of prostate cancer... - Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivationYuanjie Niu
George Whipple Lab for Cancer Research, Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
Cancer Res 68:7110-9. 2008..PSA small interfering RNA or smaller molecules that can degrade PSA protein may be developed as alternative approaches to treat the prostate cancer... - Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growthZhiming Yang
George Whipple Laboratory for Cancer Research, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, New York 14642, USA
Mol Endocrinol 21:343-58. 2007..The finding that a protein can modulate AR function without direct interaction with AR might provide a new therapeutic approach, with fewer side effects, to battle prostate cancer by targeting AR indirectly... - Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cellsMujib M Rahman
George Whipple Laboratory for Cancer Research, Department of Biochemistry, University of Rochester Medical Center, New York 14642, USA
J Biol Chem 278:19619-26. 2003..ARA70 may, thus, be a critical target for developing therapeutic agents against AR-mediated progression of prostate cancer... - Androgen receptor coregulators in prostate cancer: mechanisms and clinical implicationsMujib Rahman
George Whipple Laboratory for Cancer Research, Department of Biochemistry, and the Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA
Clin Cancer Res 10:2208-19. 2004 - Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1Aimee M Johnson
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Elmwood Avenue, Rochester, New York, USA
BMC Urol 8:7. 2008..Furthermore, because BC growth in UPII-SV40T mice is exophytic, we speculated BC growth was dependent on angiogenesis and angiogenesis was, in turn, androgen responsive... - Androgen deprivation therapy for prostate cancer: current status and future prospectsHiroshi Miyamoto
George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and the Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
Prostate 61:332-53. 2004..In order to improve overall survival, novel treatment strategies that prolong the androgen-dependent state and that are useful for androgen-independent disease based on specific molecular mechanisms need to be identified... - Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cellsYichun Zheng
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
Endocr Relat Cancer 18:451-64. 2011..Our results indicate that AR activation upregulates the expression of EGFR and ERBB2 in bladder cancer cells. AR signals may thus contribute to the progression of bladder cancer via regulation of the EGFR/ERBB2 pathways... - Molecular basis for the antiandrogen withdrawal syndromeHiroshi Miyamoto
George Whipple Laboratory for Cancer Research, Department of Pathology, and the Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA
J Cell Biochem 91:3-12. 2004.... - Androgen deprivation therapy for prostate cancerEric A Singer
Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA
Expert Opin Pharmacother 9:211-28. 2008.... - Promotion of bladder cancer development and progression by androgen receptor signalsHiroshi Miyamoto
Department of Pathology, University of Rochester Medical Center, 601 Elmwood Ave, Box 626, Rochester, NY 14642, USA
J Natl Cancer Inst 99:558-68. 2007..Unlike prostate cancer, human bladder cancer is not generally considered to be dependent on hormone activity. We investigated the possible involvement of androgens and the androgen receptor (AR) in bladder cancer... - ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptorZhiming Yang
George Whipple Lab for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and the Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA
Nat Med 13:348-53. 2007..Collectively, our results point to a better therapeutic and preventative approach to treating SBMA, by disrupting the interaction between AR and AR coregulators... - Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?Hiroshi Miyamoto
Department of Pathology, University of Rochester Medical Center, NY 14642, USA
Nat Clin Pract Oncol 2:236-7. 2005 - Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancerHiroshi Miyamoto
Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
Mol Carcinog 44:1-10. 2005..We hypothesize that androgen deprivation, in combination with inhibition of the Akt, COX-2, and MMP-9 pathways, delays the androgen-independent transition and has more beneficial effects than hormonal therapy alone... - Expression of semenogelins I and II and its prognostic significance in human prostate cancerAnastasia M Canacci
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
Prostate 71:1108-14. 2011..Little is known about the role of semenogelins, seminal plasma proteins that play critical roles in semen clotting and subsequent liquefaction in the presence of zinc and prostate-specific antigen, in human malignancies... - Role of frozen section analysis of testicular/paratesticular fibrous pseudotumours: a five-case experienceJennifer Gordetsky
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY Department of Urology, University of Rochester Medical Center, Rochester, New York, USA
Can Urol Assoc J 5:E47-51. 2011..Very little is known about the role of frozen section analysis (FSA) for these lesions in terms of intraoperative surgical management... - Early versus late hormonal therapy for prostate cancerHiroshi Miyamoto
Department of Urology, University of Rochester, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA
Curr Urol Rep 5:188-96. 2004.... - A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growthHiroshi Miyamoto
George Whipple Laboratory for Cancer Research, Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
J Biol Chem 277:4609-17. 2002..Further studies may provide a new therapeutic approach for blocking AR-mediated prostate cancer growth...